Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

Cisplatin 18pembrolizumab 12Paclitaxel 9Carboplatin 9Radiotherapy 5Gemcitabine 4Fluorodeoxyglucose F18 4Colposcopy 4Brachytherapy 4fludarabine 3durvalumab 3Surveys and Questionnaires 3Radiation 3Flow Cytometry 3Cyclophosphamide 3Biopsy 3Bevacizumab 3toripalimab 2fludarabine phosphate 2atezolizumab 2aldesleukin 2adavosertib 2Zoledronic Acid 2Topotecan 2Nivolumab 2Neoadjuvant Therapy 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Interleukin-2 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uterine Cervical Neoplasms × tisotumab vedotin × Clear all
NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Seagen Inc.

Phase 1/2 Terminated
214 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡